Literature DB >> 16847774

Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity.

Barry S Oken1, Kristin Flegal, Daniel Zajdel, Shirley S Kishiyama, Jesus Lovera, Bridget Bagert, Dennis N Bourdette.   

Abstract

To evaluate the potential effects of medications with central nervous system (CNS) activity on cognitive function and fatigue in multiple sclerosis (MS), we performed a retrospective analysis of medication use among 70 subjects with MS who were participating in a clinical trial for evaluation of the effects of yoga and exercise programs on cognition and fatigue. Among these MS subjects, 74% were taking at least one potentially CNS-active medication. These 70 subjects were divided into two groups: those taking at least one CNS-active medication (n = 52) and those not on any medications with potential CNS activity (n = 18). We compared assessments of cognitive function and fatigue using an analysis of covariance. MS subjects on CNS-active medication had greater impairment on measures of processing speed, sustained attention, and fatigue than those not on these medications. While these findings do not establish a causal relationship between medication use and cognitive impairment and fatigue, the data indicate that researchers need to control for use of CNS-active medications when conducting studies of cognitive impairment and fatigue in MS subjects.

Entities:  

Mesh:

Year:  2006        PMID: 16847774     DOI: 10.1682/jrrd.2004.11.0148

Source DB:  PubMed          Journal:  J Rehabil Res Dev        ISSN: 0748-7711


  8 in total

1.  Teaching mindfulness meditation to adults with severe speech and physical impairments: An exploratory study.

Authors:  Elena Goodrich; Helané Wahbeh; Aimee Mooney; Meghan Miller; Barry S Oken
Journal:  Neuropsychol Rehabil       Date:  2014-10-23       Impact factor: 2.868

2.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

Review 3.  Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

Authors:  D W Langdon; M P Amato; J Boringa; B Brochet; F Foley; S Fredrikson; P Hämäläinen; H-P Hartung; L Krupp; I K Penner; A T Reder; R H B Benedict
Journal:  Mult Scler       Date:  2011-12-21       Impact factor: 6.312

4.  Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.

Authors:  Pekka Rapeli; Carola Fabritius; Hely Kalska; Hannu Alho
Journal:  BMC Clin Pharmacol       Date:  2011-08-21

Review 5.  Characteristics of randomized controlled trials of yoga: a bibliometric analysis.

Authors:  Holger Cramer; Romy Lauche; Gustav Dobos
Journal:  BMC Complement Altern Med       Date:  2014-09-02       Impact factor: 3.659

6.  DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?

Authors:  Steven H P van de Pavert; Nils Muhlert; Varun Sethi; Claudia A M Wheeler-Kingshott; Gerard R Ridgway; Jeroen J G Geurts; Maria Ron; Tarek A Yousry; Alan J Thompson; David H Miller; Declan T Chard; Olga Ciccarelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-29       Impact factor: 10.154

7.  What is the relevance of quality of life assessment for patients with attention impairment?

Authors:  Karine Baumstarck; Mohamed Boucekine; Irina Klemina; Françoise Reuter; Valérie Aghababian; Anderson Loundou; Jean Pelletier; Pascal Auquier
Journal:  Health Qual Life Outcomes       Date:  2013-04-25       Impact factor: 3.186

8.  Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices.

Authors:  Karine Baumstarck; Mohamed Boucekine; Laurent Boyer; Valérie Aghababian; Nathalie Parola; Françoise Reuter; Anderson Loundou; Christophe Lançon; Jean Pelletier; Pascal Auquier
Journal:  BMC Neurol       Date:  2014-04-08       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.